Abstract
The COVID-19 pandemic has created massive demand for widespread, distributed tools for detecting SARS-CoV-2 genetic material. The hurdles to scalable testing include reagent and instrument accessibility, availability of highly-trained personnel, and large upfront investment. Here we showcase an orthogonal pipeline we call CREST (Cas13-based, Rugged, Equitable, Scalable Testing) that addresses some of these hurdles. Specifically, CREST pairs commonplace and reliable biochemical methods (PCR) with low-cost instrumentation, without sacrificing detection sensitivity. By taking advantage of simple fluorescence visualizers, CREST allows for a binary interpretation of results. CREST may provide a point- of-care solution to increase the distribution of COVID-19 surveillance.
Competing Interest Statement
The authors have declared no competing interest.
Footnotes
↵a kosik{at}lifesci.ucsb.edu
↵b carolinaarias{at}ucsb.edu
↵c daa{at}lifesci.ucsb.edu
↵d mzw{at}ucsb.edu
↵† These authors are co-senior authors
In our updated version we added even more de-identified patient samples to Figure 4. We added a supplemental figure (Fig. S5) showing a small pilot study comparing CREST to RT-qPCR in 95 asymptomatic individuals. We also updated our demonstration that CREST could be coupled with a column-free RNA extraction method called PEARL.
